For myotwin, BIO-Europe once again provided a valuable opportunity to showcase the latest advancements in human tissue models and digital cardiac simulations. Particularly encouraging was the strong interest in reliable, human-relevant data for cardiovascular drug development, a key topic in many conversations and a clear indication of the growing importance of this approach within the industry.
The exchange at the NRW joint booth was once again a highlight for myotwin. Numerous constructive and open discussions took place with committed companies from North Rhine-Westphalia. The strong local network and highly positive feedback underscored the relevance of new solutions emerging from the NRW region.
myotwin draws a very positive conclusion. The third participation in BIO-Europe further increased international visibility and generated valuable starting points for future partnerships. With many new insights from Vienna and the support of a strong regional ecosystem, the team now embarks on upcoming projects with fresh momentum.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary TrinityScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
